Search
Dexamethasone Treatment Options
A collection of 1446 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
853 - 864 of 1446
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combin... Read More
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
04/04/2020
Locations: Children's Hospital of Alabama, Birmingham, Alabama +133 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Completed
The purpose of this study is to determine the maximum tolerated dose (MTD) of pomalidomide in combination with bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2020
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia +5 locations
Conditions: Multiple Myeloma
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with multiple myeloma.
PURPOSE: Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients with multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/31/2020
Locations: St. Mary's/Duluth Clinic Health System, Duluth, Minnesota +36 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Completed
The goal of this clinical trial is to determine the toxicity and also the efficacy of a treatment that includes the following treatment: Two medications, bortezomib and dexamethasone (or BD), followed by autologous stem cell transplantation, and a prolonged course of treatment with bortezomib and dexamethasone after transplantation. This type of treatment has been very effective in multiple myeloma. However, there is little experience with this treatment in patients who have Monoclonal Immunoglo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2020
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +4 locations
Conditions: Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Completed
This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib) administered orally.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2020
Locations: Tufts Medical Center, Boston, Massachusetts +9 locations
Conditions: Light-Chain Amyloidosis
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Completed
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment, and to to estimate the partial hematologic response rate (PHR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2020
Locations: Tufts Medical Center, Boston, Massachusetts +5 locations
Conditions: AL Amyloidosis
Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME
Unknown
The objective of this study is to test the hypothesis that following the use of intravitreal dexamethasone implant for the treatment of DME, there will be an observable increase in the capillary density plexus as denoted by the quantitative assessment of the superficial capillary plexus on OCTA, as well as a decrease in size of the foveal avascular zone (FAZ).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/16/2020
Locations: Retina Macula Specialists of Miami, LLC, North Miami Beach, Florida +1 locations
Conditions: Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Completed
This partially randomized phase I/II trial studies the side effects and best dose of anakinra when given together with lenalidomide and dexamethasone in treating patients with early stage multiple myeloma. Biological therapies, such as lenalidomide and anakinra, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2020
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Completed
Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell death. Combination of pan-DAC and protease inhibition by co-treatment with panobinostat (PAN) and bortezomib (BTZ) has demonstrated synergistic cytotoxicity in vitro and in vivo in pre-clinical experiments. Furthermore, clinical experience in advanced multiple myeloma (MM) pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2020
Locations: Novartis Investigative Site, Phoenix, Arizona +209 locations
Conditions: Multiple Myeloma
Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery
Completed
To test the hypothesis that preoperative injections along the levator ani muscles and pudendal nerve with bupivacaine and dexamethasone improve pain control after vaginal apical reconstructive surgery. A three-arm, double-blinded, randomized controlled trial of a total of 75 women will be performed.
The study population will be adult women (\>18 years of age) with uterovaginal or vaginal vault prolapse who have been scheduled for native tissue vaginal reconstructive surgery which includes an ap... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2020
Locations: Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania
Conditions: Pelvic Organ Prolapse, Surgery, Postoperative Pain
Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery
Terminated
Currently medications injected intravitreally in previously vitrectomized eyes have a very short half-life due to enhanced clearance of the drug. The use of the Ozurdex (dexamethasone) implant may allow sustained levels of steroid delivery to patients with diabetic macular edema that have undergone prior vitrectomy. The sustained steroid levels may lead to improved central retinal thickness measurements and improved visual acuity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2020
Locations: Lahey Medical Center, One Essex Center Drive, Peabody, Massachusetts
Conditions: Diabetic Macular Edema
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Completed
The primary objective of this study is to determine the efficacy of PCI-32765, both as a single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and refractory Multiple Myeloma (MM)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2020
Locations: SITE-13, La Jolla, California +10 locations
Conditions: Multiple Myeloma
853 - 864 of 1446